肾移植后免疫复合物及补体介导的膜增生性肾小球肾炎复发
这项多中心回顾性队列纳入1981至2021年间11家医院220例因膜增生性肾小球肾炎(MPGN)致终末期肾病的肾移植受者,其中补体介导34例、免疫复合物介导186例。中位随访79个月期间81例(37%)发生移植肾衰竭,54例(25%)在中位16个月后复发,补体介导型与异常蛋白血症者复发率更高。复发后肾结局异质,作者认为需要更有效且个体化的治疗。
要点
- 220例MPGN肾移植受者中补体介导34例、免疫复合物介导186例。
- 移植肾衰竭81例(37%),主要预测因素为排斥反应和疾病复发。
- 复发54例(25%),中位复发时间16个月,补体介导型为复发预测因素。
核心结论
- 约四分之一因MPGN致自体肾病者会在移植肾出现临床复发,补体介导型或伴异常蛋白血症者尤甚。
- 现有治疗下复发的肾脏结局异质,作者认为需要更有效且个体化的治疗。
研究设计与样本
- 多中心回顾性队列,纳入1981至2021年间11家医院220例经活检证实的自体肾病MPGN肾移植受者。
- 研究组包括补体介导MPGN 34例和免疫复合物介导MPGN 186例。
- 收集人口学、临床和预后相关的组织学参数,主要结局为至肾衰竭时间、至MPGN复发时间和复发后疾病缓解。
主要发现
- 中位随访79个月,81例(37%)达到肾衰竭,主要预测因素为排斥反应发生和疾病复发。
- 54例(25%)在中位16个月后复发,异常蛋白血症者复发率67%、补体介导MPGN者复发率62%。
- 多变量模型中补体介导MPGN为复发的预测因素,33例在复发后达到肾衰竭。
- 未缓解的主要决定因素为复发时间早(<15个月)、复发时估算肾小球滤过率<30 mL/min/1.73 m2和血清白蛋白<3.5 g/dL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Membranoproliferative glomerulonephritis (MPGN) represents a histologic pattern of glomerular injury that may be due to several aetiologies. Few studies have comprehensively analysed the recurrence of MPGN according to the current classification system. METHODS: We collected a multicentre, retrospective cohort of 220 kidney graft recipients with biopsy-proven native kidney disease due to MPGN between 1981 and 2021 in 11 hospitals. Demographic, clinical and histologic parameters of prognostic interest were collected. The main outcomes were time to kidney failure, time to recurrence of MPGN and disease remission after recurrence. RESULTS: The study group included 34 complement-mediated and 186 immune complex-mediated MPGN. A total of 81 patients (37%) reached kidney failure in a median follow-up of 79 months. The main predictors of this event were the development of rejection episodes and disease recurrence. In all, 54 patients (25%) had a disease recurrence in a median of 16 months after kidney transplantation. The incidence of recurrence was higher in patients with dysproteinaemia (67%) and complement-mediated MPGN (62%). In the multivariable model, complement-mediated MPGN emerged as a predictor of recurrence. A total of 33 patients reached kidney failure after recurrence. The main determinants of no remission were early time to recurrence (<15 months), estimated glomerular filtration rate <30 mL/min/1.73 m2 and serum albumin <3.5 g/dL at the time of recurrence. CONCLUSIONS: One-fourth of the patients with native kidney disease due to MPGN developed clinical recurrence in the allograft, especially in cases with complement-mediated disease or in those associated with dysproteinaemia. The kidney outcomes of disease recurrence with currently available therapies are heterogeneous and thus more effective and individualized therapies are needed.
引用
- Caravaca-Fontán F, Polanco N, Villacorta B, et al. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation. Nephrol Dial Transplant. 2023. PMID: 35404425. doi:10.1093/ndt/gfac148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。